Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Leuk Res. 2023 Sep;132:107354. doi: 10.1016/j.leukres.2023.107354. Epub 2023 Jul 12.
The treatment patterns for patients with newly diagnosed acute myeloid leukemia (AML) were compared between 2013 and 16 and 2021-22 in a real-world setting. A significantly higher proportion of patients age 70 and over received non-intensive therapy (NIT) in 2021-22 as compared with 2013-16 (65 % vs 44 %, p = 0.014), with a corresponding reduction in the proportion receiving either intensive therapy or no antileukemic treatment. Treatment patterns among patients < age 70 were unchanged. The complete response rate in the NIT group was 69 % in 2021-22 vs. 24 % in 2013-16 (p < 0.001); the overall survival (OS) of NIT patients was 11.5 months in 2021-22 vs. 7.8 months in 2013-16. Older patients from rural areas were more likely to decline therapy than those from urban regions. The increase in the proportion of patients opting for NIT may be related to the availability of more effective treatment options. Although outcomes are improving, the OS with NIT remains suboptimal.
在真实环境中，比较了 2013-16 年和 2021-22 年新诊断为急性髓系白血病（AML）患者的治疗模式。与 2013-16 年相比，2021-22 年年龄在 70 岁及以上的患者接受非强化治疗（NIT）的比例显著更高（65%比 44%，p=0.014），接受强化治疗或无抗白血病治疗的比例相应降低。年龄<70 岁的患者治疗模式没有变化。NIT 组的完全缓解率在 2021-22 年为 69%，而在 2013-16 年为 24%（p<0.001）；NIT 患者的总生存率（OS）在 2021-22 年为 11.5 个月，而在 2013-16 年为 7.8 个月。来自农村地区的老年患者比来自城市地区的患者更有可能拒绝治疗。选择 NIT 的患者比例增加可能与更有效的治疗选择有关。尽管结果在改善，但 NIT 的 OS 仍然不理想。
